

# **Vaxart to Present at the JMP Securities Life Sciences Private Company Conference on Friday, October 17, 2014**

JMP Securities Life Sciences Conference 2014  
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart Inc., a privately held, clinical-stage company developing recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, MD, chief executive officer, will provide an overview of the company at the JMP Securities Life Sciences Private Company Conference on Friday, October 17, 2014, at 8:40 a.m. EDT. The event will be held at Le Parker Meridian Hotel in New York. Dr. Latour will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Investors can contact their JMP sales representative to schedule a meeting.

## **About Vaxart**

Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable for delivering a wide range of protein vaccine antigens, such as those used in currently marketed influenza, hepatitis B and human papilloma virus (HPV) vaccines. Care Capital is the lead investor in the company and its largest shareholder. For more information, please visit [www.vaxart.com](http://www.vaxart.com).

## **Contacts**

Vaxart

Wouter Latour, 650-550-3511

or

For Investor Inquiries:

Burns McClellan

Kimberly Minarovich, 212-213-0006

[kminarovich@burnsmc.com](mailto:kminarovich@burnsmc.com)